Global and United States Anaplastic Lymphoma Kinase ALK Inhibitor Market Insights, Forecast to 2027

Table of Contents

1 Study Coverage

• 1.1 Anaplastic Lymphoma Kinase ALK Inhibitor Product Introduction
• 1.2 Market by Type
  • 1.2.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Growth Rate by Type
  • 1.2.2 First Generation ALK Inhibitor
  • 1.2.3 Second Generation ALK Inhibitor
  • 1.2.4 Third Generation ALK Inhibitor
• 1.3 Market by Application
  • 1.3.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Growth Rate by Application
  • 1.3.2 Hospital Pharmacy
  • 1.3.3 Retail Pharmacy
  • 1.3.4 Others
• 1.4 Study Objectives
• 1.5 Years Considered

2 Executive Summary

• 2.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size, Estimates and Forecasts
  • 2.1.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue 2016-2027
  • 2.1.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales 2016-2027
• 2.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor, Market Size by Region: 2016 VS 2021 VS 2027
• 2.3 Anaplastic Lymphoma Kinase ALK Inhibitor Historical Market Size by Region (2016-2021)
  • 2.3.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Retrospective Market Scenario in Sales by Region: 2016-2021
  • 2.3.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Retrospective Market Scenario in Revenue by Region: 2016-2021
• 2.4 Anaplastic Lymphoma Kinase ALK Inhibitor Market Estimates and Projections by Region (2022-2027)
  • 2.4.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Forecast by Region (2022-2027)
  • 2.4.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Forecast by Region (2022-2027)

3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Competitor Landscape by Players

• 3.1 Global Top Anaplastic Lymphoma Kinase ALK Inhibitor Manufacturers by Sales
  • 3.1.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Manufacturer (2016-2021)
  • 3.1.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Manufacturer (2016-2021)
• 3.2 Global Top Anaplastic Lymphoma Kinase ALK Inhibitor Manufacturers by Revenue
  • 3.2.1 Key Anaplastic Lymphoma Kinase ALK Inhibitor Manufacturers Covered: Ranking by Revenue
  • 3.2.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Manufacturers (2016-2021)
  • 3.2.3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Share by Manufacturers (2016-2021)
  • 3.2.4 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Concentration Ratio (CR5 and HHI) (2016-2021)
  • 3.2.5 Global Top 10 and Top 5 Companies by Anaplastic Lymphoma Kinase ALK Inhibitor Revenue in 2020
  • 3.2.6 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Price by Manufacturers
• 3.4 Global Anaplastic Lymphoma Kinase ALK Inhibitor Manufacturing Base Distribution, Product Types
  • 3.4.1 Anaplastic Lymphoma Kinase ALK Inhibitor Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Anaplastic Lymphoma Kinase ALK Inhibitor Product Type
  • 3.4.3 Date of International Manufacturers Enter into Anaplastic Lymphoma Kinase ALK Inhibitor Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2016-2027)

• 4.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size by Type (2016-2021)
  • 4.1.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2016-2021)
  • 4.1.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Type (2016-2021)
  • 4.1.3 Anaplastic Lymphoma Kinase ALK Inhibitor Average Selling Price (ASP) by Type (2016-2021)
• 4.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Forecast by Type (2022-2027)
  • 4.2.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Forecast by Type (2022-2027)
  • 4.2.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Forecast by Type (2022-2027)
  • 4.2.3 Anaplastic Lymphoma Kinase ALK Inhibitor Average Selling Price (ASP) Forecast by Type (2022-2027)

5 Breakdown Data by Application (2016-2027)

• 5.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size by Application (2016-2021)
  • 5.1.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2016-2021)
  • 5.1.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Application (2016-2021)
  • 5.1.3 Anaplastic Lymphoma Kinase ALK Inhibitor Price by Application (2016-2021)
• 5.2 Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Forecast by Application (2022-2027)
  • 5.2.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Forecast by Application (2022-2027)
  • 5.2.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Forecast by Application (2022-2027)
  • 5.2.3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Price Forecast by Application (2022-2027)

6 United States by Players, Type and Application

• 6.1 United States Anaplastic Lymphoma Kinase ALK Inhibitor Market Size YoY Growth 2016-2027
  • 6.1.1 United States Anaplastic Lymphoma Kinase ALK Inhibitor Sales YoY Growth 2016-2027
  • 6.1.2 United States Anaplastic Lymphoma Kinase ALK Inhibitor Revenue YoY Growth 2016-2027
  • 6.1.3 United States Anaplastic Lymphoma Kinase ALK Inhibitor Market Share in Global Market 2016-2027
• 6.2 United States Anaplastic Lymphoma Kinase ALK Inhibitor Market Size by Players (International and Local Players)
  • 6.2.1 United States Top Anaplastic Lymphoma Kinase ALK Inhibitor Players by Sales (2016-2021)
  • 6.2.2 United States Top Anaplastic Lymphoma Kinase ALK Inhibitor Players by Revenue (2016-2021)
• 6.3 United States Anaplastic Lymphoma Kinase ALK Inhibitor Historic Market Review by Type (2016-2021)
  • 6.3.1 United States Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Type (2016-2021)
  • 6.3.2 United States Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Type (2016-2021)
  • 6.3.3 United States Anaplastic Lymphoma Kinase ALK Inhibitor Price by Type (2016-2021)
• 6.4 United States Anaplastic Lymphoma Kinase ALK Inhibitor Market Estimates and Forecasts by Type (2022-2027)
  • 6.4.1 United States Anaplastic Lymphoma Kinase ALK Inhibitor Sales Forecast by Type (2022-2027)
  • 6.4.2 United States Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Forecast by Type (2022-2027)
  • 6.4.3 United States Anaplastic Lymphoma Kinase ALK Inhibitor Price Forecast by Type (2022-2027)
• 6.5 United States Anaplastic Lymphoma Kinase ALK Inhibitor Historic Market Review by Application (2016-2021)
  • 6.5.1 United States Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Application (2016-2021)
  • 6.5.2 United States Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Application (2016-2021)
  • 6.5.3 United States Anaplastic Lymphoma Kinase ALK Inhibitor Price by Application (2016-2021)
• 6.6 United States Anaplastic Lymphoma Kinase ALK Inhibitor Market Estimates and Forecasts by Application (2022-2027)
  • 6.6.1 United States Anaplastic Lymphoma Kinase ALK Inhibitor Sales Forecast by Application (2022-2027)
  • 6.6.2 United States Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Forecast by Application (2022-2027)
  • 6.6.3 United States Anaplastic Lymphoma Kinase ALK Inhibitor Price Forecast by Application (2022-2027)

7 North America

• 7.1 North America Anaplastic Lymphoma Kinase ALK Inhibitor Market Size YoY Growth 2016-2027
• 7.2 North America Anaplastic Lymphoma Kinase ALK Inhibitor Market Facts & Figures by Country
  • 7.2.1 North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2016-2021)
  • 7.2.2 North America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2016-2021)
  • 7.2.3 United States
  • 7.2.4 Canada

8 Asia Pacific

• 8.1 Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Market Size YoY Growth 2016-2027
• 8.2 Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Market Facts & Figures by Region
  • 8.2.1 Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Region (2016-2021)
  • 8.2.2 Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Region (2016-2021)
  • 8.2.3 China
  • 8.2.4 Japan
  • 8.2.5 South Korea
  • 8.2.6 India
  • 8.2.7 Australia
  • 8.2.8 Australia
  • 8.2.9 Indonesia
  • 8.2.10 Thailand
  • 8.2.11 Malaysia

9 Europe

• 9.1 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Market Size YoY Growth 2016-2027
• 9.2 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Market Facts & Figures by Country
  • 9.2.1 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2016-2021)
  • 9.2.2 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2016-2021)
  • 9.2.3 Germany
  • 9.2.4 France
  • 9.2.5 U.K.
  • 9.2.6 Italy

10 Latin America

• 10.1 Latin America Anaplastic Lymphoma Kinase ALK Inhibitor Market Size YoY Growth 2016-2027
• 10.2 Latin America Anaplastic Lymphoma Kinase ALK Inhibitor Market Facts & Figures by Country
  • 10.2.1 Latin America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2016-2021)
  • 10.2.2 Latin America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2016-2021)
  • 10.2.3 Mexico
  • 10.2.4 Brazil
  • 10.2.5 Argentina
  • 10.2.6 Colombia

11 Middle East and Africa

• 11.1 Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Market Size YoY Growth 2016-2027
• 11.2 Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Market Facts & Figures by Country
  • 11.2.1 Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2016-2021)
  • 11.2.2 Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2016-2021)
  • 11.2.3 Turkey
  • 11.2.4 Saudi Arabia
  • 11.2.5 UAE

12 Company Profiles

• 12.1 Astellas Pharma
  • 12.1.1 Astellas Pharma Corporation Information
  • 12.1.2 Astellas Pharma Description and Business Overview
  • 12.1.3 Astellas Pharma Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2016-2021)
  • 12.1.4 Astellas Pharma Anaplastic Lymphoma Kinase ALK Inhibitor Products Offered
  • 12.1.5 Astellas Pharma Recent Development
• 12.2 AstraZeneca
  • 12.2.1 AstraZeneca Corporation Information
  • 12.2.2 AstraZeneca Description and Business Overview
  • 12.2.3 AstraZeneca Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2016-2021)
  • 12.2.4 AstraZeneca Anaplastic Lymphoma Kinase ALK Inhibitor Products Offered
  • 12.2.5 AstraZeneca Recent Development
• 12.3 Betta Pharmaceuticals
  • 12.3.1 Betta Pharmaceuticals Corporation Information
  • 12.3.2 Betta Pharmaceuticals Description and Business Overview
  • 12.3.3 Betta Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2016-2021)
  • 12.3.4 Betta Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Products Offered
  • 12.3.5 Betta Pharmaceuticals Recent Development
• 12.4 GlaxoSmithKline
  • 12.4.1 GlaxoSmithKline Corporation Information
  • 12.4.2 GlaxoSmithKline Description and Business Overview
  • 12.4.3 GlaxoSmithKline Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2016-2021)
  • 12.4.4 GlaxoSmithKline Anaplastic Lymphoma Kinase ALK Inhibitor Products Offered
  • 12.4.5 GlaxoSmithKline Recent Development
• 12.5 Merck
  • 12.5.1 Merck Corporation Information
  • 12.5.2 Merck Description and Business Overview
  • 12.5.3 Merck Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2016-2021)
  • 12.5.4 Merck Anaplastic Lymphoma Kinase ALK Inhibitor Products Offered
  • 12.5.5 Merck Recent Development
• 12.6 Novartis
  • 12.6.1 Novartis Corporation Information
  • 12.6.2 Novartis Description and Business Overview
  • 12.6.3 Novartis Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2016-2021)
  • 12.6.4 Novartis Anaplastic Lymphoma Kinase ALK Inhibitor Products Offered
  • 12.6.5 Novartis Recent Development
• 12.7 Pfizer
  • 12.7.1 Pfizer Corporation Information
  • 12.7.2 Pfizer Description and Business Overview
  • 12.7.3 Pfizer Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2016-2021)
  • 12.7.4 Pfizer Anaplastic Lymphoma Kinase ALK Inhibitor Products Offered
  • 12.7.5 Pfizer Recent Development
• 12.8 Roche
  • 12.8.1 Roche Corporation Information
  • 12.8.2 Roche Description and Business Overview
  • 12.8.3 Roche Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2016-2021)
  • 12.8.4 Roche Anaplastic Lymphoma Kinase ALK Inhibitor Products Offered
  • 12.8.5 Roche Recent Development
• 12.9 Takeda Pharmaceuticals
  • 12.9.1 Takeda Pharmaceuticals Corporation Information
  • 12.9.2 Takeda Pharmaceuticals Description and Business Overview
  • 12.9.3 Takeda Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2016-2021)
  • 12.9.4 Takeda Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Products Offered
  • 12.9.5 Takeda Pharmaceuticals Recent Development
• 12.10 Turning Point Therapeutics
  • 12.10.1 Turning Point Therapeutics Corporation Information
  • 12.10.2 Turning Point Therapeutics Description and Business Overview
  • 12.10.3 Turning Point Therapeutics Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2016-2021)
  • 12.10.4 Turning Point Therapeutics Anaplastic Lymphoma Kinase ALK Inhibitor Products Offered
  • 12.10.5 Turning Point Therapeutics Recent Development
• 12.11 Astellas Pharma
  • 12.11.1 Astellas Pharma Corporation Information
  • 12.11.2 Astellas Pharma Description and Business Overview
  • 12.11.3 Astellas Pharma Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2016-2021)
  • 12.11.4 Astellas Pharma Anaplastic Lymphoma Kinase ALK Inhibitor Products Offered
  • 12.11.5 Astellas Pharma Recent Development

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Anaplastic Lymphoma Kinase ALK Inhibitor Industry Trends
• 13.2 Anaplastic Lymphoma Kinase ALK Inhibitor Market Drivers
• 13.3 Anaplastic Lymphoma Kinase ALK Inhibitor Market Challenges
• 13.4 Anaplastic Lymphoma Kinase ALK Inhibitor Market Restraints

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Anaplastic Lymphoma Kinase ALK Inhibitor Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details